Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
FAIL · Does not pass the screen
49.43 USD
Price as of 6 Nov 2026Daily close, not a live quote
Screened 2026-11-06 · the tape above runs as of 20:08 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price49.43 USD at the 6 Nov 2026 close
Our value readUndervalued vs our fair value, as of 6 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.18, read 2026-11-02
Ethical does not pass the values gate
Price49.43 USD
Fair value74.00
Ethical score70.0/100
Value readUndervaluedas of 6 Nov 2026
Our investment reviews on this name
2026-11-06Read Accumulation44.79+10.4% to today ✓Markdown gives way to Accumulation after an 8% slide in 5 weeks
2026-10-02Read Markdown48.87+1.1% to today Accumulation gives way to Markdown after a 20% slide in 5 weeks
2026-08-27Read Accumulation60.87-18.8% to today Markdown gives way to Accumulation after a 32% rise in 8 weeks
2026-07-02Read Markdown46.13+7.2% to today First review on file: Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Enliven Therapeutics, Inc. holds its Accumulation at $49.43. Elevated stress, defensive posture warranted, held for 55 days.
As held on the ledger · 2026-11-06
Phase
Accumulation
Quantitative state
Elevated stress, defensive posture warranted, held for 55 days
Price at the screen
$49.43
Valuation
N/A trailing · -20.39 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.36
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.08%
Below 33%
Interest-bearing debt is just 0.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
76.39%
Below 33%
Interest-bearing cash and securities are 76.4% of assets, above the one-third limit.
Fail
Receivables
20.77%
Below 49%
Money owed to the company is 20.8% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Enliven Therapeutics,'s business is fine, but its cash and interest-bearing securities are about 76% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ELVN's ethical verdict changes
Today ELVN does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 6 Nov 2026: it trades at roughly a 39% discount to our $74.00 fair value.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. A 33.2% discount to the base estimate.
Where our models see it going: fair-value estimate $74.00, with a range of $69.00 to $82.00, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Early cancer drug bets face thin data walls
A clinical stage biotech chasing small molecule inhibitors for cancer feels like funding a lab notebook that might one day become a pill. Enliven sits at that exact point, with its lead candidate still in Phase 1 and zero product revenue to date. We pass because the opportunity rating shows none and the ethical screen returns insufficient data on basic financial ratios.
The numbers underline the gap. Forward P/E sits at negative 22.9 times, profit margins are zero and return on equity is negative 27 percent. Nine analysts still carry a strong buy consensus and a 62 dollar median target above the current 53.20 price, yet those forecasts rest on future trial success that remains unproven.
Risk sits around the complete lack of financial history and ethical metrics, plus the usual binary outcome of early oncology trials. Currency or cyclical exposure does not apply here; instead the absence of any moat rating or ratio coverage leaves the position too thin to assess properly. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ELVN trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-07Accumulation$49.43+10.4%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 10.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 9% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (8 analysts) rates it none, with a mean price target of $57. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 5.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 9% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (8 analysts) rates it none, with a mean price target of $57. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-05Markdown$47.25+5.4%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 5.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 9% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (8 analysts) rates it none, with a mean price target of $57. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04Markdown$44.83+7.2%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 7.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 9% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (8 analysts) rates it none, with a mean price target of $57. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markdown$41.82+5.9%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 5.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 9% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (8 analysts) rates it none, with a mean price target of $57.
2026-10-21Markdown$39.49-3.6%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 3.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 0% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (8 analysts) rates it none, with a mean price target of $57.
2026-10-14Markdown$40.98-16.1%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 16.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 52% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (8 analysts) rates it none, with a mean price target of $57.
2026-10-02Markdown · changed$48.87-19.7%Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 19.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 52% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (8 analysts) rates it none, with a mean price target of $57.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 14.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 52% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (8 analysts) rates it none, with a mean price target of $57.
2026-07-27Markdown$53.20+15.3%Entry 4
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 15.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 52% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (8 analysts) rates it none, with a mean price target of $57.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
